正面比较：Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) 和 Nephros (NASDAQ:NEPH)

Nephros (NASDAQ:NEPH) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Nephros and Health Sciences Acquisitions Co. 2, as provided by MarketBeat.

Get Nephros alerts:

Nephros presently has a consensus price target of $5.25, suggesting a potential upside of 344.92%. Given Nephros'  higher possible upside, equities research analysts plainly believe Nephros is more favorable than Health Sciences Acquisitions Co. 2.

Volatility and Risk

Nephros has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500. Comparatively, Health Sciences Acquisitions Co. 2 has a beta of 0.09, suggesting that its share price is 91% less volatile than the S&P 500.

Earnings and Valuation

This table compares Nephros and Health Sciences Acquisitions Co. 2's gross revenue, earnings per share and valuation.

Health Sciences Acquisitions Co. 2 has lower revenue, but higher earnings than Nephros.

Profitability

This table compares Nephros and Health Sciences Acquisitions Co. 2's net margins, return on equity and return on assets.

Institutional & Insider Ownership

42.1% of Nephros shares are owned by institutional investors. Comparatively, 89.7% of Health Sciences Acquisitions Co. 2 shares are owned by institutional investors. 8.6% of Nephros shares are owned by company insiders. Comparatively, 21.9% of Health Sciences Acquisitions Co. 2 shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Health Sciences Acquisitions Co. 2 beats Nephros on 6 of the 10 factors compared between the two stocks.

About Nephros

Nephros, Inc. develops and sells high performance water solutions to the medical and commercial markets in the United States. The company operates in three segments: Water Filtration, Pathogen Detection, and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also develops and sells real-time water testing systems to provide actionable data on waterborne pathogens; and medical device products for patients with renal disease, including a 2nd generation hemodiafiltration system for the treatment of patients with end stage renal disease. In addition, it offers water filters that improve the taste and odor of water, as well as reduce biofilm, bacteria, and scale build-up in downstream equipment under the Nephros and AETHER brands for the food service, hospitality, convenience store, and health care markets. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.

About Health Sciences Acquisitions Co. 2

Health Sciences Acquisitions Corporation 2 does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or related business combination with one or more businesses in the biopharma and medical technology sectors in North America or Europe. Health Sciences Acquisitions Corporation 2 was incorporated in 2020 and is based in New York, New York.

Receive News & Ratings for Nephros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nephros and related companies with MarketBeat.com's FREE daily email newsletter.